immunology funding
30 open opportunities tagged immunology, across federal agencies and private foundations. Sorted by deadline.
Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional)
Research Objectives Atopic Dermatitis (AD) is a chronic inflammatory pruritic skin disease that affects approximately 11% of children and up to 9% of adults in the United States.
13 review criteria on fileLimited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)
Research Objectives The NIEHS invites qualified investigators from domestic institutions of higher education to submit an application for an SRP Center grant.
22 review criteria on fileLimited Competition: Specific Pathogen Free Macaque Colonies to Support HIV/AIDS Research (U42 Clinical Trial Not Allowed)
The purpose of this Notice of Funding Opportunity (NOFO) is to provide continuing support for specific pathogen-free (SPF) macaque colonies previously funded under the auspices of PAR-21-089 and PAR-18-669 that support Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) research.
5 review criteria on fileNIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
Background The mission of the National Institute of Allergy and Infectious Diseases (NIAID) is to conduct and support basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.
13 review criteria on fileNIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
Background The mission of the National Institute of Allergy and Infectious Diseases (NIAID) is to conduct and support basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.
7 review criteria on fileMetastasis Research Network (U54 Clinical Trial Not Allowed)
Purpose The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will contribute to developing a comprehensive and cohesive understanding of cancer metastasis.
12 review criteria on fileEnhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions.
3 review criteria on fileEnhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions using a milestone-driven, biphasic award mechanism.
3 review criteria on fileCausal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed)
6 years.25 billion fewer life years for the United States population.
3 review criteria on fileNIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
Background Clinical trials are one strategy NIAID uses to improve prevention, diagnosis, and treatment of infectious, immunologic, and allergic diseases in addition to understanding the mechanisms of these diseases.
3 review criteria on fileThe Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)
Purpose Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications proposing research projects that use integrative systems-level approaches to address a specific question in metastasis research.
3 review criteria on fileEarly Immune System Development and Ontogeny (R01 Clinical Trial Optional)
The purpose of this Notice of Funding Opportunity (NOFO) is to further elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART).
3 review criteria on fileCCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical Trial Not Allowed)
The civilian chemical threat spectrum includes chemical warfare agents, toxic industrial chemicals and materials, pharmaceutical-based agents, and others that have been collectively identified by the United States Government (USG) as Chemicals of Concern (CoCs)., disasters or attacks).
3 review criteria on fileBioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
Purpose The goal for a bioengineering research grant (BRG) is to foster the development of an innovative technology, model, technique, design, or method that has the potential for a significant impact on biomedical research by infusing principles and concepts from the quantitative sciences.
3 review criteria on fileMolecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites research grant applications (R01) for the development and application of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo .
3 review criteria on fileContinuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
Cardiovascular complications remain the leading cause of death among individuals with T1D despite the management of traditional risk factors such as high blood glucose, high blood pressure, and elevated cholesterol.
3 review criteria on fileAssay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment,…
3 review criteria on fileAssay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as…
3 review criteria on fileINCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
The INCLUDE Transformative Research Award Program supports collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in understanding the biology of Down syndrome or related co-occurring conditions, or development of new treatments for…
3 review criteria on fileINCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome (R21 Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) invites researchers to submit applications for support of new exploratory and developmental research projects that address important gaps in Down syndrome research.
3 review criteria on fileINCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)
Purpose The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome.
3 review criteria on fileCommunity-Based Participatory Research to Advance Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All (UG3/UH3 Clinical Trial Optional)
This Notice of Funding Opportunity (NOFO) solicits UG3/UH3 phased, cooperative agreement research applications to evaluate, implement, and/or test population-based interventions to policies, programs, and/or practices that promote the integration of services, systems, and/or values by leveraging cross-sector partnerships in communities.
3 review criteria on fileScience Track Award for Research Transition (START) Program (R03, Clinical Trial Optional)
The Science Track Award for Research Transition (START) programs have been key initiatives of the National Institute on Drug Abuse (NIDA).
3 review criteria on fileCommunity Engagement Evaluation and Data Coordination (CEED) Hub to Advance Data and Practice Transformation for Optimizing Oral Health for All (U01, Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) seeks applications for a Community Engagement Evaluation and Data coordination hub (CEED) for the Community-Based Participatory Research (CBPR) consortium: Advancing Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All.
3 review criteria on fileDiabetes Research Centers (P30 Clinical Trial Optional)
Background According to the CDC, the prevalence of diabetes mellitus in the United States continues to rise over time.6% of the US Population) and about twice that prevalence in those over 65.
9 review criteria on fileMaximizing Investigators' Research Award (MIRA) (R35 - Clinical Trial Optional)
Purpose To enhance grant funding efficiency and efficacy, the NIGMS established the Maximizing Investigators' Research Award (MIRA) , a single grant that provides support for an investigator's NIGMS-aligned research program, encompassing all projects within their laboratory that align with the scientific mission of NIGMS .
7 review criteria on fileBrightFocus Foundation — The Immune Landscape of the Human Optic Nerve Head
The Immune Landscape of the Human Optic Nerve Head BrightFocus Foundation BrightFocus is a premier funder of groundbreaking research in an urgent effort to discover cures for Alzheimer’s disease, macular degeneration, and glaucoma. Search Translation EN ES FR DE ID About the Disease What is Glaucoma?
Open Philanthropy — Announcing the Strep A Vaccine Fund
Announcing the Strep A Vaccine Fund | Coefficient Giving Skip to Content Coefficient Giving Research / Announcements May 26, 2026 Announcing the Strep A Vaccine Fund By Alexander Berger and Katharine Collins Most people in wealthy countries know Strep A as the cause of strep throat, an uncomfortable but easily treated childhood illness.
Engineering of Biomedical Systems
TheEngineering of Biomedical Systemsprogram is part of the Engineering Biology and Health cluster, which also includes: 1) theBiophotonicsprogram; 2) theBiosensingprogram; 3) theCellular and Biochemical Engineeringprogram; and 4) theDisability and Rehabilitation Engineeringprogram.
2 review criteria on file · agency frameworkPlant Biotic Interactions
The Plant Biotic Interactions (PBI) program supports research on the processes that mediate beneficial and antagonistic interactions between plants and their viral, bacterial, oomycete, fungal, plant, and invertebrate symbionts, pathogens and pests.
2 review criteria on file · agency frameworkSee which immunology opportunities fit your work
An account is free and shows the full announcement, the review criteria reviewers score you against, and whether you are actually eligible — including the windows that close before the deadline does.
No card required.